Interview with Erika Koppers, COO & GM, Roche SA
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Address: 7 Malibongwe Drive
Fontainebleau, Randburg
Gauteng,South Africa
Tel: + 27 11 792-7120
Web: http://www.omnimed.co.za/
OmniMed (Pty) Ltd was founded in 1960 and its main activity was the manufacture of sterile intravenous solutions under license to a leading German manufacturer. The name of the Company at the time was Remedia Medical.
In time, the Company diversified into other forms of pharmaceutical manufacture but as it evolved, it embarked upon new ventures focusing on the hospital and specialist doctor market. It acquired new licenses offering a broad spectrum of hospital consumables and equipment.
Today OmniMed owes its diversity to its ability to adapt to changing markets. Due to its long-standing presence in the market, leading product portfolio and strong customer service, OmniMed is well known in both the Private and Public Health Care sectors.
Life-saving technologies, as well as products that improve the quality of life have always been the trademark of OmniMed.
OmniMed also provides administration and distribution services to BioMerieux SA a leading French Diagnostic company on a fee for service basis.
The manufacturing operation is located in Johannesburg and OmniMed has a fully owned well-established subsidiary in Namibia.
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
South Africa carries one of the world’s most disproportionate disease burdens, the worst of so-called westernised diseases, such as cardiac disease, diabetes etc on the one hand and the developmental…
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed…
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
See our Cookie Privacy Policy Here